TRAIL (TNF-Related Apoptosis-Inducing Ligand), also known as Apo2L, is a member of the TNF ligand family. TRAIl is a type II membrane protein which may be expressed as a full-length, cell surface associated protein as well as in a soluble form. Both surface and soluble forms of TRAIL rapidly induce apoptosis on a wide range of cell lines. TRAIL has been shown to cause apoptotic death in either tumorigenic or transformed cells, but not in normal cells. TRAIL-mediated apoptosis has been shown to involve the activation of caspases, and is blocked by over-expression of the caspase-1 protease inhibitor, CrmA. TRAIL has also been reported to induce the transcription factor NF-κB in a cell type-specific manner. Two cognate TRAIL receptors DR4, and DR5, as well as two decoy receptors, DcR1/TRID and DcR2/TRUNDD have been identified. TRAIL has been shown to be involved in T cell cytotoxicity, but the exact physiological role TRAIL plays in T-cell mediated cytotoxicity remains to be elucidated. The RIK-2 antibody recognizes human TRAIL. Human TRAIL cDNA was transferred to an expression vector and transfected into the 2PK-3 mouse B cell lymphoma cell line to generate stable transfectants, which were then used to immunize mice. The RIK-2 clone was selected based on its ability to block cytotoxic activity. TRAIL has been renamed as CD253 recently. Flow cytometric analsis of TRAIL. Profile of human TRAIL/2PK-3 cell line analyzed on a FACScan™ .
TNFSF10
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Flow Cytometry : Applications include flow cytometry (0.25-1.0 μg/1x10e6 cells). 550515 Rev. 4 Page 1 of 2 Blocking: The RIK-2 antibody is useful to block TRAIL-induced apoptosis. The no azide/low endotoxin format (NA/LE), Cat. No. 550912, is recommended for in vitro blocking assays.
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Storage Comment
Store undiluted at 4°C.
Kayagaki, Yamaguchi, Nakayama, Kawasaki, Akiba, Okumura, Yagita: "Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 162, Issue 5, pp. 2639-47, (1999) (PubMed).
Marsters, Pitti, Donahue, Ruppert, Bauer, Ashkenazi: "Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA." in: Current biology : CB, Vol. 6, Issue 6, pp. 750-2, (1997) (PubMed).
Mariani, Matiba, Armandola, Krammer: "Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells." in: The Journal of cell biology, Vol. 137, Issue 1, pp. 221-9, (1997) (PubMed).
Sheridan, Marsters, Pitti, Gurney, Skubatch, Baldwin, Ramakrishnan, Gray, Baker, Wood, Goddard, Godowski, Ashkenazi: "Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors." in: Science (New York, N.Y.), Vol. 277, Issue 5327, pp. 818-21, (1997) (PubMed).
Pitti, Marsters, Ruppert, Donahue, Moore, Ashkenazi: "Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family." in: The Journal of biological chemistry, Vol. 271, Issue 22, pp. 12687-90, (1996) (PubMed).
Wiley, Schooley, Smolak, Din, Huang, Nicholl, Sutherland, Smith, Rauch, Smith: "Identification and characterization of a new member of the TNF family that induces apoptosis." in: Immunity, Vol. 3, Issue 6, pp. 673-82, (1996) (PubMed).
Target
TRAIL (TNFSF10)
(Tumor Necrosis Factor (Ligand) Superfamily, Member 10 (TNFSF10))